Theralase Technologies Inc (TLTFF)

[123414]

Theralase Technologies receives a target raise from Research-Capital

123414 Still long TLTFF.

The 67% CR@ 18/24 months is unmatched.

Those full dose patients are becoming dominate in the study.

Under-treaded patients are still in the mix but getting reduced.
AND... Now the kicker... the undertreated patients were not treated in the protocol of the study.

Read what the analysis says about all the one dose patients.

TLTFF on track and still solid as heck.

That's why that analyists moved his rating to .95usd / 1.20cad

He nailed it before.

Stay tuned sports fan the race is just heating up.

Theralase Technologies receives a target raise from Research-Capital

https://www.cantechletter.com/2022/04/theralase-technologies-receives-a-target-raise-from-research-capital/